Replimune Group, Inc.

Report overall survival data for the IGNYTE-3 randomized confirmatory trial

Deadline not yet reached (1526 days left)

Announced: 30 Jul 2026
Due: 31 Dec 2030

Deadline
Met
Late
Not met
Today

What the company said

“IGNYTE-3 randomized confirmatory trial ongoing with OS data expected in 2030”

SourceReplimune Group, Inc. Form 8-K press release, 2026-07-30
FilingSEC filing index
Deadline as statedin 2030
Deadline used31 Dec 2030, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-REPL-002762
Cite as https://keptindex.org/c/KI-C-2026-REPL-002762/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2030.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: IGNYTE-3 trial OS data
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-REPL-002762 · Corrections policy